Check 35,000+ stocks against 26 valuation models and 37 quality factors

Maccura Biotechnology Co Ltd (300463) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Maccura Biotechnology Co Ltd ¥1.35, price ¥9.53, upside -85.8%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · CN · ISIN CNE1000020H3

MB Thin data Sep 24, 2026

Maccura Biotechnology Co Ltd

300463 · SHE

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥1.35 · Strongly overvalued (−85.8%)

!Quality 49/100

!Weak Growth (revenue 5y −10.1 %/yr)

!Loss-making · -2.4% net margin (TTM)

!Low debt · negative free cash flow

!Mixed vs. peers (5/12)

!Narrow moat 20/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear ¥1.00 to bull ¥1.74 Growth analysisrevenue history, year by year Quality 49/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Maccura Biotechnology Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥8.11 – ¥45.19 · fair‑value band ¥1.00 – ¥1.74 · the ¥9.53 price screens above the ¥1.35 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Maccura Biotechnology Co in your weekly email

Every Wednesday you see whether Maccura Biotechnology Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such as digital PCR and extraction systems, and PCR kits; urinalysis analyzer systems and semi-automatic urine analyzers; and hemostasis solutions, including coagulation and semi-automatic coagulation analyzers. It provides clinical chemistry products, such as glycohemoglobin and protein analyzer, biochemistry systems, and chemistry regents; blood group product solutions; and pathology solutions, such as a liquid-based cytology processing system. Maccura Biotechnology Co.Ltd was founded in 1994 and is headquartered in Chengdu, China.

Stock analysis

Maccura Biotechnology Co Ltd (300463) currently trades at ¥9.53, while our model-based Fair Value estimate is ¥1.35, 85.8% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥6.95 per share, and 1 of the 8 models we run sit above the ¥9.53 price.

Bear case: the Earnings-Based group reads lowest at ¥0.9800, and 7 of the 8 models stay below the price. Evidence for this calculation is low.

Scenario range: ¥1.00 (bear) to ¥1.74 (bull), the price of ¥9.53 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Maccura Biotechnology Co Ltd reported revenue of 2.2B CNY in FY2025 versus 4.0B CNY in FY2021, a compound −14.1%/yr. Reported net income was −35.8M CNY in FY2025.

Key figures

Market cap 5.8B CNY (≈ $860M) · P/S ratio 2.40 · EPS (TTM) ¥−0.0800 · Dividend yield 1.6% · Net margin −1.7% · Return on equity −1.0% · Return on assets (EBIT) 7.1% · Operating margin 4.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −86%, 300463 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (¥0.9800 to ¥10.05). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.

Bear ¥1.00 Fair Value ¥1.35 Bull ¥1.74

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

EPV ¥0.8900 ¥0.9800 ¥1.05 74

ROIC Compounder ¥0.8900 ¥0.9800 ¥1.05 72

Gordon GGM ¥1.08 ¥1.94 ¥2.67 68

All 8 models by family

Earnings-Based

EPV ¥0.8900 ¥0.9800 ¥1.05 74

Dividend Discount

Gordon GGM ¥1.08 ¥1.94 ¥2.67 68

DDM Multi-Stage ¥1.08 ¥1.58 ¥2.04 67

Multiples

EV/EBIT ¥1.39 ¥1.78 ¥2.16 66

EV/EBITDA ¥7.60 ¥10.05 ¥12.50 67

EV/Revenue ¥1.06 ¥1.42 ¥1.77 54

Asset-Based

NCAV (Graham) ¥5.19 ¥6.95 ¥10.38 54

Economic Profit

ROIC Compounder ¥0.8900 ¥0.9800 ¥1.05 72

Open the full fair value analysis →

Notify me when 300463 reaches fair value

Put 300463 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 49 · Market factors (momentum, volatility) 41

Profitability 15

Margins and returns on capital today

Quality Growth 46

Are margins and returns improving?

Cashflow 31

Earnings quality: real cash, not paper profit

Fin. Strength 68

Balance sheet, leverage, solvency risk

Investment 67

Disciplined investing over empire-building

Low Volatility 81

Calm price path (market factor)

Momentum 30

Price trend over the last 3–12 months (market factor)

52W Momentum 16

Distance to the 52-week high (market factor)

Net Issuance 89

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100

Revenue is shrinking: the last year, the last three and the last five years are all negative.

Revenue growth 1 year

−14.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−15.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−10.1%

Start year 2020 (pandemic). Over 10 years: +7.4% a year

Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+10.7%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

26.7% (2020) → 2.5% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

300463 screens overvalued: fair value 86% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Maccura Biotechnology Co Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 136 stocks

Beats the industry median on 5/11 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 49 · Below median

Fair Value upside −85.8% · Bottom 25%

Profitability

Return on assets −0.4% · Below median

Net margin (TTM) −2.4% · Below median

Operating margin (TTM) 4.3% · Below median

Growth and dividend

Revenue growth −6.9% · Bottom 25%

Dividend yield (TTM) 1.6% · Above median

Balance sheet

Debt / equity 0.08× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.14× · Cheapest 25%

P/S (TTM) 0.40× · Cheapest 25%

EV/EBITDA 2.3× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)0 · sector 28

PAST (return on equity)0 · sector 10

HEALTH (low debt)96 · sector 93

DIVIDEND (yield)33 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$675.05	$686.04	+2%
Danaher Corporation DHR	$221.55	$209.18	−6%
WuXi AppTec Co 603259	¥162.40	¥178.64	+10%
Agilent Technologies, Inc A	$175.03	$64.17	−63%
Lonza Group LONN	CHF 565.60	CHF 151.69	−73%
IQVIA Holdings IQV	$270.37	$297.41	+10%
Waters Corporation WAT	$433.54	$106.46	−75%
Illumina, Inc ILMN	$271.90	$295.60	+9%
IDEXX Laboratories, Inc IDXX	$533.44	$495.84	−7%
Mettler-Toledo International Inc MTD	$1,512	$644.24	−57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Maccura Biotechnology Co Ltd · Fair Value
¥1.35 −86%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/300463" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Maccura Biotechnology Co Ltd · Fair Value</span><br><b style="font-size:20px">¥1.35</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−86%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Maccura Biotechnology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300463

Frequently asked questions

Is Maccura Biotechnology Co Ltd (300463) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of ¥1.35 versus a price of ¥9.53, about −86% upside (overvalued).

What is the fair value of 300463?

Our model-based fair value for Maccura Biotechnology Co Ltd is ¥1.35 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥9.53.

What is the quality score of 300463?

Maccura Biotechnology Co Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Maccura Biotechnology Co Ltd (300463)?

Our model-based price target is the fair value of ¥1.35 (as of Sep 24, 2026) from 8 valuation models. Cautious scenario ¥1.00, optimistic scenario ¥1.74. It is a calculation from audited fundamentals, not an analyst target.

What is the Maccura Biotechnology Co Ltd stock forecast for 2026?

Our models put fair value at ¥1.35, about −86% upside versus a price of ¥9.53 (overvalued). Cautious scenario ¥1.00, optimistic scenario ¥1.74. The calculation is refreshed regularly with new filings.

What is the revenue of Maccura Biotechnology Co Ltd (300463)?

Maccura Biotechnology Co Ltd reported trailing-twelve-month revenue of about 2.1B CNY (latest available figure, as of Sep 24, 2026).

Does Maccura Biotechnology Co Ltd pay a dividend?

Maccura Biotechnology Co Ltd currently shows a dividend yield of about 1.63% relative to its recent price (as of Sep 24, 2026).

What is the intrinsic value of Maccura Biotechnology Co Ltd (300463)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Maccura Biotechnology Co Ltd it is ¥1.35 per share (as of Sep 24, 2026), against a price of ¥9.53. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).

Is Maccura Biotechnology Co Ltd stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 300463 trades above its calculated fair value: price ¥9.53, fair value ¥1.35, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 300463?

No. The price is what the market pays today (¥9.53); the fair value is what the company's own numbers justify (¥1.35). For Maccura Biotechnology Co Ltd the two are ¥8.18 per share apart. That gap is exactly why we show both numbers side by side.

How much is Maccura Biotechnology Co Ltd worth?

The market values Maccura Biotechnology Co Ltd at about 5.8B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥9.53; our models calculate a fair value of ¥1.35 per share.

What do the bullish and bearish scenarios say about 300463?

Our models span a range for Maccura Biotechnology Co Ltd: cautious scenario ¥1.00, base ¥1.35, optimistic ¥1.74 per share (as of Sep 24, 2026, price ¥9.53). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Maccura Biotechnology Co Ltd (300463)?

Balance-sheet figures for Maccura Biotechnology Co Ltd (as of Sep 24, 2026): return on equity −1.0%, debt of 0.08 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.

How far is 300463 from its 52-week high?

Maccura Biotechnology Co Ltd trades at ¥9.53, about 33% below its 52-week high of ¥14.20 and 18% above the low of ¥8.11 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.35 is for.

Which stocks are comparable to Maccura Biotechnology Co Ltd?

From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Maccura Biotechnology Co Ltd stock attractive at the current price?

The data as of Sep 24, 2026: price ¥9.53, calculated fair value ¥1.35 (−86%), Quality Score 49/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 300463 calculated?

We run Maccura Biotechnology Co Ltd through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.35, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Maccura Biotechnology Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Maccura Biotechnology Co Ltd (300463)?

The closing price on Sep 30, 2026 was ¥9.53. Our model-based fair value is ¥1.35, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Maccura Biotechnology Co Ltd right now?

The price sits above even our optimistic bull case (¥1.74). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.

Where does the earnings growth of Maccura Biotechnology Co Ltd (300463) come from?

Earnings per share at Maccura Biotechnology Co Ltd grew +3.4 % a year from 2013 to 2024. Broken into its drivers: revenue per share +11.1 %, EBIT margin −7.9 %, tax rate +1.5 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Maccura Biotechnology Co Ltd

How large is the market capitalisation of Maccura Biotechnology Co Ltd (300463)?

The market capitalisation of Maccura Biotechnology Co Ltd is 5.8B CNY (≈ $860M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Maccura Biotechnology Co Ltd (300463)?

The price-to-sales ratio of Maccura Biotechnology Co Ltd is 2.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Maccura Biotechnology Co Ltd (300463)?

Earnings per share at Maccura Biotechnology Co Ltd are ¥−0.0800. Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Maccura Biotechnology Co Ltd (300463)?

The dividend yield of Maccura Biotechnology Co Ltd is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Maccura Biotechnology Co Ltd (300463)?

The net margin of Maccura Biotechnology Co Ltd is −1.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Maccura Biotechnology Co Ltd (300463)?

The return on equity (ROE) of Maccura Biotechnology Co Ltd is −1.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Maccura Biotechnology Co Ltd (300463)?

On an EBIT basis the return on assets of Maccura Biotechnology Co Ltd is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Maccura Biotechnology Co Ltd (300463)?

The operating margin of Maccura Biotechnology Co Ltd is 4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Maccura Biotechnology Co Ltd (300463)?

Revenue at Maccura Biotechnology Co Ltd is growing −6.9% versus a year earlier (3y avg −15.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Maccura Biotechnology Co Ltd (300463)?

Earnings per share at Maccura Biotechnology Co Ltd are growing −62.0% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Maccura Biotechnology Co Ltd (300463) generate?

The free cash flow of Maccura Biotechnology Co Ltd is −147M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Maccura Biotechnology Co Ltd (300463) carry?

The net debt of Maccura Biotechnology Co Ltd is 114M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Maccura Biotechnology Co Ltd in the live analysis

One click puts Maccura Biotechnology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.